CBA Pharma, Inc. is a specialty pharmaceutical company headquartered in Lexington, Kentucky.
CBA Pharma, Inc. is organized to exclusively manufacture, market, license and distribute to the medical oncology community a drug, CBT-1®, developed to be an effective treatment for cancer that has developed or may develop drug resistance to chemotherapy.
Multiple Drug Resistance (MDR) is the phenomenon whereby cells become resistant to a variety of chemotherapy drugs. Resistance of cancer cells to chemotherapy remains the major cause of treatment failure.
CBA Pharma Vision Statement
The unifying principle of "Many Minds, One Heart"® is the core of the philosophical foundation of CBA Pharma. It best reflects the pioneering research and product development successes achieved over the past decade leading to the creation of this company. It signifies the focused intent of many individuals (employees, shareholders, consultants, clinical investigators, etc.) toward a common vision.
"Many Minds, One Heart"®